1. Ravitch JR, Bryant BJ, Reese MJ, et al. In vivo and in vitro studies of the potential for drug interactions involving the anti-retroviral 1592 in humans. In: 5th Conference on Retroviruses and Opportunistic InfectionsChicago 1–5 February 1998:230–6 Abstract 634.
2. Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1;Kessler;Clin Infect Dis,2002
3. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults;Kumar;Antimicrob Agents Chemother,1999
4. Vernazza PL, Katlama C, Clotet B, et al. Intensification of stable background (SBG) antiretroviral therapy (ART) with Ziagen (ABC, 1592). In: 6th Conference on Retroviruses and Opportunistic InfectionsChicago Jan 31–Feb 4 1999:230–6.
5. Coming therapies: abacavir;Staszewski;Int J Clin Pract Suppl,1999